Human papillomavirus-associated head and neck squamous cell carcinomas (HPV-HNSCC) originate in the tonsils, the major lymphoid organ that orchestrates immunity to oral infections. Despite its location, the virus escapes immune elimination during malignant transformation and progression. Here, we provide evidence for the role of the PD-1:PD-L1 pathway in HPV-HNSCC immune resistance. We demonstrate membranous expression of PD-L1 in the tonsillar crypts, the site of initial HPV infection.
INTRODUCTION
Human papillomavirus (HPV) is recognized as the causative agent of a growing subset of head and neck cancers (1, 2) . It is now estimated that HPV is responsible for up to 80% of oropharyngeal cancers in the United States (3, 4) . HPV-associated head and neck squamous cell carcinomas (HPV-HNSCC) differ from tobacco-related head and neck cancers in several ways (5, 6) . The patients tend to be younger in age, lack a significant tobacco and/or alcohol history, and have improved clinical outcomes. The virus-related tumors arise from the deep crypts within the lymphoid tissue of the tonsil and base of tongue and the majority can be distinguished from tobacco-related head and neck cancers by the characteristic infiltration of lymphocytes in the stroma and tumor nests (7) . Nevertheless, despite this profound inflammatory response, HPV-HNSCCs are able to evade immune surveillance, persist, and grow. Author Manuscript Published OnlineFirst on January 3, 2013; DOI: 10.1158/0008-5472. CAN-12-2384 as well as autoimmunity. In the context of cancer, in which immune responses are directed against antigens specifically or selectively expressed by tumor cells, these immune checkpoints can represent major obstacles to the generation and maintenance of clinically meaningful anti-tumor immunity. Therefore, efforts have been made in the clinical arena to investigate blockade of immune checkpoints as a novel therapeutic approach to cancer. CTLA-4 and programmed cell death-1 (PD-1) are two such checkpoint receptors being actively targeted in the clinic. Ipilimumab, a monoclonal antibody (mAb) that blocks CTLA-4, demonstrated an overall survival benefit in patients with advanced metastatic melanoma in a randomized phase III clinical trial; however, it was associated with significant immune-related toxicities (8) . In a first-in-human clinical trial, a blocking mAb against PD-1 (BMS-936558, MDX-1106/ONO-4538) was evaluated in patients with advanced metastatic melanoma, colorectal cancer, castrateresistant prostate cancer, non-small-cell lung cancer (NSCLC), and renal cell carcinoma (RCC). In this study, the antibody was well-tolerated and there was evidence of clinical activity in all of the evaluated histologies except prostate cancer (9) . In a subset of patients, tumor cell surface or "membranous" expression of the major PD-1 ligand, PD- 
MATERIALS AND METHODS

Human Subjects
Patients undergoing surgical resection for tonsil (palatine or lingual) cancer were enrolled in this study that was approved by the Johns Hopkins Institutional Review Board, after providing informed consent. HPV status was determined by in situ hybridization (ISH) and p16 immunohistochemistry (IHC). Briefly, 5 uM sections from formalin-fixed paraffin embedded (FFPE) tumor blocks were evaluated with the Ventana HPV III Family16 probe set. Punctate hybridization signals localized to tumor cell nuclei defined a HPV-positive tumor. P16 expression was evaluated using the Ultra view polymer detection kit (Ventana Medical Systems, Inc. Tucson, AZ) on a Ventana
BenchmarkXT autostainer (Ventana); expression was scored as positive if strong and diffuse nuclear and cytoplasmic staining was present in 70% of the tumor. All slides were interpreted by a head and neck pathologist (WHW).
A separate cohort of patients (both adults and pediatric patients, <2 years of age) undergoing a tonsillectomy for management of a non-malignant process such as tonsil hypertrophy or chronic tonsillitis served as non-cancer controls.
Flow Cytometry Analysis
Circulating peripheral blood mononuclear cells (PBMCs) isolated by density gradient centrifugation and infiltrating lymphocytes dissociated from fresh tumor or nonmalignant tonsil digests were stained with the following mAbs: anti-human CD3-PERCP, CD8-APC, CD4-FITC (BD Biosciences, Mountain View, CA), and anti-human PD-1 (MDX-1106, fully human IgG4, 10 ug/ml, BMS, New York, NY) or an isotype control, anti-diphtheria toxin human IgG4 (BMS). Anti-human IgG4-PE (SouthernBiotech, 
Programmed Death-1 (PD-1) receptor expressed by CD8+ TILs in HPV-HNSCC
In order to further evaluate the relevance of the PD-1:PD-L1 pathway in the development of HPV-HNSCC, we compared the frequency of PD-1 expression on TILs and PBMCs isolated from patients with HPV-HNSCC vs. patients with a non-malignant tonsil process. We found that PD-1 expression by both CD4+ and CD8+ T cells was higher in tonsil tissue as compared to the peripheral blood of patients with either HPV-HNSCC or with benign, chronically inflamed tonsils (all p < 0.05; Figures 2A and B) . There was no significant difference in the frequency of PD-1 expressing CD4+ T cells infiltrating tumors vs. benign tonsils (p=0.31) (Figure 2A) Two patterns of cellular distribution of PD-L1 have been described: membranous (cell surface) and cytoplasmic (9, 12, 14) . Among 20 HPV-HNSCC samples examined in our study, 14 (70%) expressed PD-L1 and all of these (14 of 14) displayed cell surface staining on 5% of tumor cells. Furthermore, we found that nearly all (13 of 14) demonstrated staining restricted to the tumor periphery at the interface between tumor cell nests and inflammatory stroma (Figures 3D and E) , whereas only 1 of 14 demonstrated diffuse PD-L1 expression throughout the tumor nests ( Figure 3F , Table 1 ).
In order to determine if PD-L1 expression was specific to HPV-HNSCC, we evaluated 7 HPV-negative tonsil cancers and found that only 29% (2 of 7) expressed PD-L1. PD-L1 expression in HPV-negative cancers was membranous and at the tumor periphery juxtaposed to immune infiltrates, similar to HPV-HNSCC ( Table 1) .
Research. 
Association of PD-L1 expression with TILs and co-localization with tumor associated macrophages
All sixteen PD-L1-expressing HPV(+) and HPV(-) tumors were detected in the setting of a host inflammatory immune response (grades 1-3), indicating an association of PD-L1 expression with the presence of TILs ( Table 1 anti-CD1a, was performed. CD1a did not co-localize with PD-L1 (data not shown).
However, CD68 co-localized with the two observed patterns of membranous PD-L1 expression, peripheral or diffuse, in the tumor microenvironment (Figures 4E and F) . at the tumor fronts juxtaposed to the inflammatory stroma (Figures 4D and E) . (Figures 6A and B, Supplemental File 2) . This difference in IFN-γ production between the PD-1(+) and PD-1(-) TILs compared to peripheral blood T cells was highly significant (p=0.005) and suggested PD-1 expression within the tumor microenvironment marks TILs that are functionally suppressed in their capacity to produce effector cytokines and may be indeed at least partially responsible for this CAN-12-2384 suppression. Similar functional assays were performed for tumor necrosis factor (TNF)-α production and, again, a decrease in functional ability of the CD8+PD-1(+) TILs to produce TNF-α as compared to CD8+PD-1(-) TILs was observed (mean ratio 0.69, SD 0.7). However, in the peripheral blood, we did not observe a decreased ability of CD8+PD-1(+) T lymphocytes to produce TNF-α as compared to CD8+PD-1(-) T cells (mean ratio 1.26, SD 0.14).
PD-L1+CD68+ tumor associated macrophages (TAMs
We also compared the functional status of CD8+ PD-1(+) vs. CD8+PD-1(-) T cells in the peripheral blood and tissue of chronic tonsillitis patients. In contrast to TILs from cancer patients, we did not observe significant differences in the functional capacity years, compared to 57% in non-HPV-HNSCCs (6). Improved survival has been attributed to a younger patient age and enhanced tumor responsiveness to chemoradiation therapy. However, a contributing factor may also be the strong host immune response generated against these tumors. Evidence for inherent immunologic responses generated against HPV-HNSCC is the observed high frequency of TILs and inflammatory responses within these tumors. Indeed, HPV-HNSCC express foreign viral proteins, such as the E6 and E7 antigens, for which the host immune system should not be tolerant. 
